Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication

Abstract This study aimed to ascertain gene expression profile differences between progressive muscle-invasive bladder cancer (MIBC) and de novo MIBC, and to identify prognostic biomarkers to improve patients’ treatment. Retrospective multicenter study in which 212 MIBC patients who underwent radica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raquel Carrasco, Laura Izquierdo, Antoine G. van der Heijden, Juan José Lozano, Marco Franco, Mercedes Ingelmo-Torres, Fiorella L. Roldan, Montserrat Llorens, María José Ribal, Lourdes Mengual, Antonio Alcaraz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ed7ec76dffab4227a7d548c3c4634b7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed7ec76dffab4227a7d548c3c4634b7c
record_format	dspace
spelling	oai:doaj.org-article:ed7ec76dffab4227a7d548c3c4634b7c2021-12-02T11:39:39ZDifferential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication10.1038/s41598-021-85137-12045-2322https://doaj.org/article/ed7ec76dffab4227a7d548c3c4634b7c2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85137-1https://doaj.org/toc/2045-2322Abstract This study aimed to ascertain gene expression profile differences between progressive muscle-invasive bladder cancer (MIBC) and de novo MIBC, and to identify prognostic biomarkers to improve patients’ treatment. Retrospective multicenter study in which 212 MIBC patients who underwent radical cystectomy between 2000 and 2019 were included. Gene expression profiles were determined in 26 samples using Illumina microarrays. The expression levels of 94 genes were studied by quantitative PCR in an independent set of 186 MIBC patients. In a median follow-up of 16 months, 46.7% patients developed tumor progression after cystectomy. In our series, progressive MIBC patients show a worse tumor progression (p = 0.024) and cancer-specific survival (CSS) (p = 0.049) than the de novo group. A total of 480 genes were found to be differently expressed between both groups. Differential expression of 24 out of the 94 selected genes was found in an independent cohort. RBPMC2 and DSC3 were found as independent prognostic biomarkers of tumor progression and CALD1 and LCOR were identified as prognostic biomarkers of CSS between both groups. In conclusion, progressive and de novo MIBC patients show different clinical outcome and gene expression profiles. Gene expression patterns may contribute to predict high-risk of progression to distant metastasis or CSS.Raquel CarrascoLaura IzquierdoAntoine G. van der HeijdenJuan José LozanoMarco FrancoMercedes Ingelmo-TorresFiorella L. RoldanMontserrat LlorensMaría José RibalLourdes MengualAntonio AlcarazNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Raquel Carrasco Laura Izquierdo Antoine G. van der Heijden Juan José Lozano Marco Franco Mercedes Ingelmo-Torres Fiorella L. Roldan Montserrat Llorens María José Ribal Lourdes Mengual Antonio Alcaraz Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
description	Abstract This study aimed to ascertain gene expression profile differences between progressive muscle-invasive bladder cancer (MIBC) and de novo MIBC, and to identify prognostic biomarkers to improve patients’ treatment. Retrospective multicenter study in which 212 MIBC patients who underwent radical cystectomy between 2000 and 2019 were included. Gene expression profiles were determined in 26 samples using Illumina microarrays. The expression levels of 94 genes were studied by quantitative PCR in an independent set of 186 MIBC patients. In a median follow-up of 16 months, 46.7% patients developed tumor progression after cystectomy. In our series, progressive MIBC patients show a worse tumor progression (p = 0.024) and cancer-specific survival (CSS) (p = 0.049) than the de novo group. A total of 480 genes were found to be differently expressed between both groups. Differential expression of 24 out of the 94 selected genes was found in an independent cohort. RBPMC2 and DSC3 were found as independent prognostic biomarkers of tumor progression and CALD1 and LCOR were identified as prognostic biomarkers of CSS between both groups. In conclusion, progressive and de novo MIBC patients show different clinical outcome and gene expression profiles. Gene expression patterns may contribute to predict high-risk of progression to distant metastasis or CSS.
format	article
author	Raquel Carrasco Laura Izquierdo Antoine G. van der Heijden Juan José Lozano Marco Franco Mercedes Ingelmo-Torres Fiorella L. Roldan Montserrat Llorens María José Ribal Lourdes Mengual Antonio Alcaraz
author_facet	Raquel Carrasco Laura Izquierdo Antoine G. van der Heijden Juan José Lozano Marco Franco Mercedes Ingelmo-Torres Fiorella L. Roldan Montserrat Llorens María José Ribal Lourdes Mengual Antonio Alcaraz
author_sort	Raquel Carrasco
title	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
title_short	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
title_full	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
title_fullStr	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
title_full_unstemmed	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
title_sort	differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ed7ec76dffab4227a7d548c3c4634b7c
work_keys_str_mv	AT raquelcarrasco differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT lauraizquierdo differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT antoinegvanderheijden differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT juanjoselozano differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT marcofranco differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT mercedesingelmotorres differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT fiorellalroldan differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT montserratllorens differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT mariajoseribal differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT lourdesmengual differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication AT antonioalcaraz differentialgeneexpressionprofilebetweenprogressiveanddenovomuscleinvasivebladdercanceranditsprognosticimplication
_version_	1718395736863801344

Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication

Ejemplares similares